[go: up one dir, main page]

MXPA04001388A - Dispositivo de retencion gastrica expandible. - Google Patents

Dispositivo de retencion gastrica expandible.

Info

Publication number
MXPA04001388A
MXPA04001388A MXPA04001388A MXPA04001388A MXPA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A MX PA04001388 A MXPA04001388 A MX PA04001388A
Authority
MX
Mexico
Prior art keywords
gastric retention
retention device
expandable gastric
expandable
therapeutics
Prior art date
Application number
MXPA04001388A
Other languages
English (en)
Inventor
W Ayres James
Original Assignee
Oregon State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State filed Critical Oregon State
Publication of MXPA04001388A publication Critical patent/MXPA04001388A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • A61K49/0414—Particles, beads, capsules or spheres
    • A61K49/0419—Microparticles, microbeads, microcapsules, microspheres, i.e. having a size or diameter higher or equal to 1 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente aplicacion se relaciona a dispositivos de retencion gastrica formados de composiciones que comprenden materiales polimericos, tales como polisacaridos, y materiales adicionales opcionales que incluyen excipientes, terapeuticos, y diagnosticos, que residen en el estomago durante un periodo de tiempo controlado y prolongado.
MXPA04001388A 2001-08-16 2001-10-22 Dispositivo de retencion gastrica expandible. MXPA04001388A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31307801P 2001-08-16 2001-08-16
PCT/US2001/046146 WO2003015745A1 (en) 2001-08-16 2001-10-22 Expandable gastric retention device

Publications (1)

Publication Number Publication Date
MXPA04001388A true MXPA04001388A (es) 2004-05-27

Family

ID=23214285

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001388A MXPA04001388A (es) 2001-08-16 2001-10-22 Dispositivo de retencion gastrica expandible.

Country Status (14)

Country Link
EP (1) EP1416914A1 (es)
JP (1) JP2005501097A (es)
KR (1) KR20040032918A (es)
CN (1) CN1543337A (es)
BR (1) BR0117123A (es)
CA (1) CA2456976A1 (es)
CO (1) CO5670360A2 (es)
IL (1) IL160363A0 (es)
MX (1) MXPA04001388A (es)
NO (1) NO20040611L (es)
NZ (1) NZ531461A (es)
PL (1) PL368327A1 (es)
WO (1) WO2003015745A1 (es)
ZA (1) ZA200402066B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458328B1 (en) * 2001-11-21 2013-01-30 Bracco Diagnostics Inc. Formulations comprising locust bean gum as stabilizing agent and mannitol as osmotic agent for use in medical or diagnostic procedures
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
AU2007275251A1 (en) * 2006-07-19 2008-01-24 Smithkline Beecham Corporation Method for radiolabeling formulations for gamma scintigraphy assessment
CN102552103B (zh) * 2010-12-20 2013-11-20 西安力邦医药科技有限责任公司 拉米夫定固体分散体、其制备方法、药物组合物和用途
ES2981892T3 (es) 2012-06-07 2024-10-11 Epitomee Medical Ltd Dispositivo expandido
CN105899198A (zh) 2013-12-05 2016-08-24 图利普医疗有限公司 用于药物活性试剂的原位释放的滞留装置和系统
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
AU2015274451C1 (en) 2014-06-11 2019-09-12 Massachusetts Institute Of Technology Residence structures and related methods
CA2983272C (en) 2015-05-01 2023-08-29 Massachusetts Institute Of Technology Triggerable shape memory induction devices
US11576859B2 (en) 2015-10-23 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
CN108697649A (zh) 2015-12-08 2018-10-23 林德拉有限公司 用于胃驻留系统的几何构型
WO2017205844A2 (en) 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
AU2017336154B2 (en) 2016-09-30 2023-11-09 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
JP7274428B2 (ja) 2017-06-09 2023-05-16 リンドラ セラピューティクス， インコーポレイティド 放出速度調節フィルムを有する胃内滞留システム
WO2019126218A1 (en) * 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
TR201914116A2 (tr) * 2019-09-17 2021-04-21 Univ Yeditepe Doğal bi̇yomateryaller i̇le kri̇yojelleri̇n üreti̇m yöntemi̇ ve bu kri̇yojelleri̇n yumuşak doku i̇skelesi̇ veya i̇laç taşiyici si̇stem olarak kullanimi
WO2022195476A1 (en) 2021-03-15 2022-09-22 Clexio Biosciences Ltd. Gastroretentive devices for assessment of intragastric conditions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US5232704A (en) * 1990-12-19 1993-08-03 G. D. Searle & Co. Sustained release, bilayer buoyant dosage form
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
WO1999007342A1 (en) * 1997-08-11 1999-02-18 Alza Corporation Prolonged release active agent dosage form adapted for gastric retention
HUP0103632A3 (en) * 1998-09-14 2005-06-28 Ranbaxy Lab Ltd Orally administered controlled drug delivery system providing temporal and spatial control
JP2000256216A (ja) * 1999-03-04 2000-09-19 Meiji Milk Prod Co Ltd ゲル組成物
KR20030013460A (ko) * 2000-06-23 2003-02-14 테바 파마슈티컬 인더스트리즈 리미티드 치료제의 위 체류 및 방출 조절을 위한 급속 팽창성조성물과 이 조성물을 포함하는 제형

Also Published As

Publication number Publication date
NZ531461A (en) 2008-03-28
JP2005501097A (ja) 2005-01-13
BR0117123A (pt) 2004-09-28
CO5670360A2 (es) 2006-08-31
CA2456976A1 (en) 2003-02-27
EP1416914A1 (en) 2004-05-12
KR20040032918A (ko) 2004-04-17
CN1543337A (zh) 2004-11-03
IL160363A0 (en) 2004-07-25
NO20040611L (no) 2004-04-16
PL368327A1 (en) 2005-03-21
ZA200402066B (en) 2005-05-09
WO2003015745A1 (en) 2003-02-27

Similar Documents

Publication Publication Date Title
WO2005079384A3 (en) Expandable gastric retention device
MXPA04001388A (es) Dispositivo de retencion gastrica expandible.
MXPA03003515A (es) Composicion de copolimero modificadora de reologia.
IL144147A0 (en) Regulators of the pct or smoothened pathway, compositions and uses related thereto
MXPA02008398A (es) Composicion cementante de alta resistencia inicial.
AU6872201A (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
MXPA03002070A (es) Proceso de anticoncepcion y forma de administracion para el mismo.
ZA200003997B (en) Pharmaceutical compositions.
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
DE602004025338D1 (de) Polymerisierbare verbindung, copolymeres, dieses enthaltende zusammensetzung, bilderzeugungsverfahren und bilderzeugungsgeraet
HUP0401811A2 (hu) Javított vízoldékonyságú gyógyszerkészítmény és eljárás az előállítására
YU2903A (sh) Smeše heparinskih derivata polisaharida, njihovo dobijanje i farmaceutske smeše koje ih sadrže
ZA200210359B (en) Pharmaceutical compositions.
MXPA05008153A (es) Sistema de encapsulacion de material.
MX233159B (es) Composiciones para tratamientos de telas.
ZA200208307B (en) Oxadiazole derivatives having anticancer effects.
MXPA03000624A (es) Composiciones y peliculas para la elaboracion de capsulas.
IL171875A0 (en) Pioglitazone salts,such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same
AU2002212895A1 (en) N-type calcium channel antagonists for the treatment of pain
AU4324301A (en) Oxazolidinone tablet formulation
NZ525774A (en) Use of SARP-1 for the treatment and/or prevention of scleroderma
HUP0302208A3 (en) Deltamethrin-containing, water-dispersible granular material, production and use thereof
AU2002210491A1 (en) Agent having prolonged stomach retention time used to produce a longlasting saturation effect, and the use thereof
HUP0204422A3 (en) Calcium dicarboxylate ethers, methods of making the compounds, and pharmaceutical compositions containing them
GB0428306D0 (en) Compound

Legal Events

Date Code Title Description
FA Abandonment or withdrawal